Blair William & Co. IL Has $7.63 Million Position in Exact Sciences Corporation $EXAS

Blair William & Co. IL cut its position in Exact Sciences Corporation (NASDAQ:EXAS) by 14.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 139,494 shares of the medical research company’s stock after selling 24,493 shares during the period. Blair William & Co. IL owned about 0.07% of Exact Sciences worth $7,632,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Westside Investment Management Inc. raised its stake in Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after buying an additional 271 shares during the period. Country Trust Bank bought a new stake in shares of Exact Sciences in the second quarter worth about $32,000. Quent Capital LLC acquired a new stake in shares of Exact Sciences during the third quarter worth about $48,000. OFI Invest Asset Management raised its position in shares of Exact Sciences by 241.2% during the third quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock worth $59,000 after purchasing an additional 767 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Exact Sciences by 463.0% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 1,216 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 1,000 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Exact Sciences Stock Up 0.2%

Shares of Exact Sciences stock opened at $103.71 on Tuesday. The firm has a market cap of $19.80 billion, a PE ratio of -94.28, a P/E/G ratio of 2.36 and a beta of 1.41. The business’s 50 day simple moving average is $102.69 and its 200 day simple moving average is $82.52. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $103.75.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same period last year, the company posted ($0.06) EPS. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. On average, analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EXAS shares. TD Cowen cut Exact Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Evercore set a $105.00 price target on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. William Blair cut shares of Exact Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, November 20th. Robert W. Baird set a $105.00 price objective on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Mizuho restated a “neutral” rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Exact Sciences currently has an average rating of “Reduce” and an average target price of $92.13.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.